Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;13(5):e12593.
doi: 10.1111/cob.12593. Epub 2023 Jun 26.

Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post-bariatric treatment failure

Anne Lautenbach  1 , Tobias Kantowski  1 , Jonas Wagner  2 , Oliver Mann  2 , Fabian Stoll  1 , Jens Aberle  1
Affiliations

Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post-bariatric treatment failure

Anne Lautenbach et al. Clin Obes. 2023 Oct.

Abstract

About 20%-25% of patients experience weight regain (WR) or insufficient weight loss (IWL) following bariatric surgery (BS). Therefore, we aimed to retrospectively assess the effectiveness of adjunct treatment with semaglutide in patients without type 2 diabetes (T2D) with post-bariatric treatment failure over a 12 months period. Post-bariatric patients without T2D with WR or IWL (n = 29) were included in the analysis. The primary endpoint was weight loss 12 months after initiation of adjunct treatment. Secondary endpoints included change in body mass index, HbA1c, lipid profile, high sensitive C-reactive protein and liver enzymes. Total weight loss during semaglutide treatment added up to 14.7% ± 8.9% (mean ± SD, p < .001) after 12 months. Categorical weight loss was >5% in 89.7% of patients, >10% in 62.1% of patients, >15% in 34.5% of patients, >20% in 24.1% of patients and > 25% in 17.2% of patients. Adjunct treatment with semaglutide resulted in sustained weight loss regardless of sex, WR or IWL and type of surgery. Among patients with prediabetes (n = 6), 12 months treatment led to normoglycemia in all patients (p < .05). Treatment options to manage post-bariatric treatment failure are scarce. Our results imply a clear benefit of adjunct treatment with semaglutide in post-bariatric patients over a 12 months follow-up period.

Keywords: GLP-1 receptor agonist; bariatric surgery; semaglutide; treatment failure; weight regain.

PubMed Disclaimer

References

REFERENCES

    1. Heymsfield S, Aronne LJ, Eneli I, et al. Clinical perspectives on obesity treatment: challenges, gaps, and promising opportunities. NAM Perspect. 2018;8(9):1-14. doi:10.31478/201809B
    1. El Ansari W, Elhag W. Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps-a scoping review. Obes Surg. 2021;31(4):1755-1766. doi:10.1007/S11695-020-05160-5
    1. Nedelcu M, Khwaja HA, Rogula TG. Weight regain after bariatric surgery-how should it be defined? Surg Obes Relat Dis. 2016;12(5):1129-1130. doi:10.1016/J.SOARD.2016.04.028
    1. Altieri MS, Yang J, Nie L, Blackstone R, Spaniolas K, Pryor A. Rate of revisions or conversion after bariatric surgery over 10 years in the state of New York. Surg Obes Relat Dis. 2018;14(4):500-507. doi:10.1016/J.SOARD.2017.12.019
    1. Kalarchian M, Turk M, Elliott J, Gourash W. Lifestyle Management for Enhancing Outcomes after bariatric surgery. Curr Diabetes Reports. 2014;14(10):1-9. doi:10.1007/S11892-014-0540-Y

LinkOut - more resources